| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 178.7 | 197.9 | 33.4 |
| Other income | 3.7 | 2.9 | 1.2 |
| Total income | 182.4 | 200.8 | 34.6 |
| Profit before exceptional items & tax | 9.8 | 12.4 | 2.0 |
| Profit before tax | 9.8 | 12.4 | 2.0 |
| Net profit | 7.9 | 13.2 | 1.4 |
| Operating margin | 5.4% | 6.2% | 5.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +464.30% |
|---|---|
| Net profit, quarter on quarter | -40.20% |
| Revenue, year on year | +435.00% |
| Operating profit, year on year | +662.50% |
| Operating profit, quarter on quarter | -35.80% |
BSE results filing, NSE: SAIPARENT. Figures extracted from the filing.
Sai Parenterals Ltd: key numbers
- Share price
- ₹503.95
- Market cap
- ₹2,226 Cr
- Revenue (annual)
- ₹381.0 Cr
- Net profit (annual)
- ₹14.26 Cr
- P/E (TTM)
- 107.2×Sector 50.4×
- Promoter holding
- 51.16%+0.00% QoQ
- FII holding
- 4.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Parenterals Ltd
All →Sai Parenterals Annual General Meeting
Sai Parenterals held its 25th Annual General Meeting on September 10, 2026. Shareholders approved financial statements, director appointments, and various company resolutions.
Sai Parenterals Earnings Call Transcript: Key Takeaways
Management is pivoting to acquisitions after regulatory shifts blocked organic expansion in Hyderabad. While revenue growth appears strong due to the Numed consolidation, margins were hurt by high logistics costs in Australia.
Sai Parenterals Investor Presentation: Key Takeaways
Sai Parenterals is transitioning from a domestic-focused player to an export-driven CDMO/branded generic platform through major acquisitions and capacity expansion. Q1 FY27 presentation focuses on IPO proceeds variation and global accreditation strategy.
Sai Parenterals Earnings Call: Key Takeaways
Sai Parenterals reports transformational FY26 following the Noumed acquisition. Focus shifts from asset building to monetization through vertical integration and expanding the CDMO export business.
Sai Parenterals Earnings Call: Key Takeaways
Sai Parenterals reports Q4 FY26 consolidated revenue of ₹198cr and EBITDA of ₹29cr, following the Noumed acquisition. Standalone FY26 PAT grew 64% YoY.
Sai Parenterals Q3 FY26 Results: Net Loss of ₹6.7 Cr
Sai Parenterals Ltd reported revenue from operations of ₹96.2 Cr and a net loss of ₹6.7 Cr for Q3 FY26.
- Key figure
- Net loss ₹6.7 Cr